Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo Sells 10,000 Shares

Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Chirfi Guindo sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company's stock, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

• Amylyx Stock: Why the Full Pipeline Story Matters

Chirfi Guindo also recently made the following trade(s):

• On Thursday, August 6th, Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $135.57 on Friday. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.68. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a market capitalization of $334.49 billion, a PE ratio of 108.46, a P/E/G ratio of 5.73 and a beta of 0.19. The company's 50 day simple moving average is $125.25 and its two-hundred day simple moving average is $119.83.

---

---

• Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Institutional Investors Weigh In On Merck & Co., Inc.

• 3 Undervalued Names Too Cheap to Ignore

Several hedge funds have recently added to or reduced their stakes in the company. Cascade Financial Partners LLC increased its position in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after purchasing an additional 80 shares during the last quarter. Somerset Trust Co lifted its position in Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock worth $1,118,000 after buying an additional 81 shares during the last quarter. Stonebridge Financial Group LLC boosted its stake in Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock worth $1,124,000 after buying an additional 81 shares in the last quarter. Stronghold Wealth Management L.L.C. boosted its stake in Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock worth $416,000 after buying an additional 82 shares in the last quarter. Finally, Lederer & Associates Investment Counsel CA grew its position in Merck & Co., Inc. by 0.9% during the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock valued at $1,234,000 after acquiring an additional 84 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade supports the shares: Daiwa Securities raised Merck from “neutral” to “outperform” and assigned a $143 price target. Other recent research places potential fair value in the $140–$155 range, citing pipeline progress and business-development activity. Daiwa Securities analyst upgrade
• Positive Sentiment: Strong momentum and pipeline optimism: MRK touched a fresh all-time high, while analysts highlighted late-stage therapeutics and new products as potential sources of growth. Keytruda demand, oncology sales and Animal Health also helped drive recent quarterly revenue of $16.61 billion, above expectations. Merck fair value and pipeline article
• Positive Sentiment: Dividend adds income appeal: Merck declared its regular quarterly dividend of $0.85 per share, equivalent to $3.40 annually and a yield of roughly 2.5% based on the referenced trading level.
• Neutral Sentiment: Insider selling raises a modest caution flag: Executives sold shares in several recent transactions, including Jennifer Zachary’s approximately $10.7 million sale and Richard Deluca’s additional sale of roughly $1.5 million. Both executives retained meaningful holdings, so the transactions may reflect personal portfolio decisions rather than a change in company outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration remains a long-term risk: Patent expiration and rising competition could eventually pressure Merck’s largest growth driver. Investors will therefore focus on whether the pipeline and newer launches can offset future Keytruda revenue declines. Keytruda growth outlook

Analyst Ratings Changes

Several analysts have weighed in on the company. Argus raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday. Cantor Fitzgerald restated a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. BMO Capital Markets raised their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a research note on Thursday, July 9th. Finally, Barclays boosted their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $135.50.

View Our Latest Analysis on Merck & Co., Inc.

About Merck & Co., Inc.

(Get Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

See Also

• Five stocks we like better than Merck & Co., Inc.
• Asian Market Circuit Breakers Hit Stocks, Not AI Demand
• Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
• Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
• Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].